AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2012
Feb 6, 2012
29864_dirs_2012-02-06_670da86e-2f43-4306-a2df-5583ecb9a032.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2012-02-02
Reporting Person: MUELLER PETER (EVP, Global R&D, CSO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-02-02 | Common Stock | A | 14501 | $0.01 | Acquired | 148236 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-02-02 | Stock Option | $37.86 | A | 72500 | Acquired | 2022-02-01 | Common Stock (72500) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 4367 | Indirect |
Footnotes
F1: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection.
F2: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012.